Neurology and Neurosurgery - Global Neurology Academy

17-32 of 546

Immunologic Phenotyping: The Future of Personalized MG Care
Immunologic Phenotyping: The Future of Personalized MG Care
NeuroFrontiers
Immunologic Phenotyping: The Future of Personalized MG Care
Shruti Raja, MD, MHS
- Shruti Raja, MD, MHS
Untreated Thymidine Kinase 2 Deficiency: Mapping the Progressive Disease Course
Untreated Thymidine Kinase 2 Deficiency: Mapping the Progressive Disease Course
AudioAbstracts
Untreated Thymidine Kinase 2 Deficiency: Mapping the Progressive Disease Course
Ryan Quigley
- Ryan Quigley
Outcome Measures Capture Progression in Late-Onset TK2d
Outcome Measures Capture Progression in Late-Onset TK2d
NeuroFrontiers
Outcome Measures Capture Progression in Late-Onset TK2d
More Than a Myopathy: The Lived Experience of TK2d
More Than a Myopathy: The Lived Experience of TK2d
NeuroFrontiers
More Than a Myopathy: The Lived Experience of TK2d
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
NeuroFrontiers
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
Jill RachBeisel, MD
- Jill RachBeisel, MD
ADHD After 25 Years: What Have We Learned?
ADHD After 25 Years: What Have We Learned?
NeuroFrontiers
ADHD After 25 Years: What Have We Learned?
James Swanson, PhD
- James Swanson, PhD
What’s Still Missing in ADHD Care?
What’s Still Missing in ADHD Care?
NeuroFrontiers
What’s Still Missing in ADHD Care?
James Swanson, PhD
- James Swanson, PhD
Diagnosing Adult ADHD in the Social Media Era
Diagnosing Adult ADHD in the Social Media Era
NeuroFrontiers
Diagnosing Adult ADHD in the Social Media Era
Jill RachBeisel, MD
- Jill RachBeisel, MD
ADHD Is Linked to a Broad Burden of GI Symptoms
ADHD Is Linked to a Broad Burden of GI Symptoms
NeuroFrontiers
ADHD Is Linked to a Broad Burden of GI Symptoms
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
NeuroFrontiers
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
CME/CE Broadcast Replay
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
Dani Cabral, MD; David Weisman, MD
1.00 credit
- Dani Cabral, MD
- David Weisman, MD
1.00 credit
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP
Antithrombotics and Amyloid Therapy: Balancing Risk
Antithrombotics and Amyloid Therapy: Balancing Risk
MinuteCE®
Antithrombotics and Amyloid Therapy: Balancing Risk
Dani Cabral, MD; David Weisman, MD
0.50 program credits
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Talking Through Benefits, Risks, and Patient Priorities
Talking Through Benefits, Risks, and Patient Priorities
MinuteCE®
Talking Through Benefits, Risks, and Patient Priorities
Dani Cabral, MD; David Weisman, MD
0.50 program credits
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Who Is Ready for Amyloid-Targeting Therapy?
Who Is Ready for Amyloid-Targeting Therapy?
MinuteCE®
Who Is Ready for Amyloid-Targeting Therapy?
Dani Cabral, MD; David Weisman, MD
0.50 program credits
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Stroke-Like Symptoms During Treatment: Safety First
Stroke-Like Symptoms During Treatment: Safety First
MinuteCE®
Stroke-Like Symptoms During Treatment: Safety First
Dani Cabral, MD; David Weisman, MD
0.50 program credits
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits

2/7